secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2022-03-28T23:59:59+00:00
Accession:  0001193125-22-086678
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen reports FY2021 net loss $100.6M; Phase 1 ACU193 topline results expected H1 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $225.9M at Dec 31, 2021; provides runway through 2025.
- Net loss $100.6M for FY2021 includes $81.2M non-cash fair value adjustment; operating loss $19.6M.
- R&D expenses $12.3M (up from $8.0M) driven by clinical trial initiation; G&A $7.3M (up from $1.4M).
- Topline results from INTERCEPT-AD Phase 1 trial of ACU193 now expected first half of 2023 due to slower enrollment from COVID-19.
- Kim Drapkin appointed to Board of Directors effective Apr 1, 2022; three new team members added in Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522086678/0001193125-22-086678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522086678/d302531d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-086678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer